

### Infection Prevention and Control Roundtable with Acute Care Facilities

9-19-24







#### **Reach out to us!**

#### Our team:

- Deputy Commissioner: <u>Stephanie Black</u>
- Medical Director: <u>Stephanie Black</u> Michelle Funk
- Projects Administrator: <u>Shane Zelencik</u>
- Project Manager: Maria Bovee
- Infection Preventionist (IP):
  - Andrea Castillo
  - Karen Branch-Crawford
  - <u>Kim Goitia</u> (Dialysis, Outpatient, FQHCs)
- Public Health Administrator (PHA):
  - <u>Romualdo Chavez</u>
  - Maggie Li

Major role: Build infection control capacity across healthcare facilities in Chicago ACHOO Email: cdphhaiar@cityofchicago.org ACHOO Phone: 312-744-1100 NEW: ACHOO HAN page





- CDPH Important Updates
  - Antimicrobial Resistance Conference: registration is open.
  - Mpox
  - iGAS
  - Point Prevalence Surveys
- Special Topic:
  - Preparing for Respiratory Viral Season: Current Epidemiology, Reporting Changes, and Infection Control Guidance
- Discussion and Q&A



#### **Registration is OPEN!**



#### Combating Antimicrobial Resistance With Stewardship: A One Health Approach

November 19, 2024, 8:00 A.M. - 4:30 P.M. | Malcolm X College, Chicago

https://www.chicago.gov/city/en/depts/cdph/supp\_info/infectious/one-health-conference-home.html

### Important Updates: MPOX IP&C Guidance (Summary)

Important updates: MPUX IP&C Guidance (Summary)							
Patient Placement	PPE	Waste Management	EVS	Duration of Isolation	Assessing Risk in Exposed HCWs	Management of Patients with an Exposure	
<ul> <li>A patient with suspected or confirmed MPXV infection should be placed in a single-person room; special air handling is not required.</li> <li>Intubation, extubation, and any procedures likely to spread oral secretions should be performed in an airborne infection isolation room.</li> </ul>	<ul> <li>Gown</li> <li>Gloves</li> <li>Eye protection (i.e., goggles or a face shield that covers the front and sides of the face)</li> <li>N95 respirator</li> </ul>	<ul> <li>Diagnostic samples and clinical waste advises that waste contaminated with clade I or clade IIMPXV is designated as Category B infectious substances except when they contain or are contaminated with laboratory cultures of clade I MPXV. Refer to the current DOT <u>Safety</u> <u>Advisory</u> <u>Notice</u> for details.</li> </ul>	<ul> <li>Standard cleaning and disinfection procedures should be performed using an EPA-registered hospital-grade disinfectant with an emerging viral pathogen claim. Products with Emerging Viral Pathogens claims may be found on EPA's List Q.</li> <li>Soiled laundry should be gently and promptly contained in an appropriate laundry bag and never be shaken or handled in manner that may disperse infectious material.</li> <li>Activities such as dry dusting, sweeping, or vacuuming should be avoided. Wet cleaning methods are preferred.</li> </ul>	<ul> <li>Those with suspected MPXV infection should have recommended isolation precautions for mpox maintained until MPXV infection is ruled out.</li> <li>Those with confirmed MPXV infection should have recommended isolation precautions for mpox maintained until all lesions have crusted, those crusts have separated, and a fresh layer of healthy skin has formed underneath.</li> </ul>	<ul> <li>unrecognized errors during the use of PPE (e.g., self- contaminating when removing contaminated PPE) may create opportunities for transmission to HCP.</li> <li>CDC uses risk categories when assessing exposures: see definitions here: https://www.cdc.gov/poxvirus/mpox/clinicians/infection- control-healthcare.html#anchor_1660143677200</li> <li>High Risk Exposure: <ul> <li>Monitoring**: Yes</li> <li>PEP¶: Yes</li> </ul> </li> <li>Intermediate Risk Exposure: <ul> <li>Monitoring**: Yes</li> <li>PEP¶: Informed clinical decision-making recommended on an individual basis to determine whether benefits of PEP outweigh the risks</li> </ul> </li> <li>Uncertain to Minimal Risk of Exposure:</li> </ul>	<ul> <li>In general, patients in healthcare facilities who have had an MPXV exposure and are asymptomatic do not need to be isolated, but they should be monitored for 21 days.</li> <li>If a rash occurs, patients should:         <ul> <li>Be placed on empiric isolation precautions for mpox until (1) the rash is evaluated, (2) testing is performed, if indicated, and (3) the results of testing are available and are negative.</li> </ul> </li> <li>If other symptoms of mpox are present, but there is no rash, patients should:         <ul> <li>Be placed on empiric isolation precautions for mpox for 5 days after the development of any new symptom.</li> </ul> </li> </ul>	

# **iGAS:** Confirmed Cases

- Updated 6/25/2024
- Confirmed: Group A Streptococcus, identified by culture or by detection of Strep A by nucleic acid testing from a <u>normally sterile</u> <u>site</u>, in an individual who:
  - Resides in a residential facility
  - Is postpartum
  - Is postsurgical
  - Was hospitalized at the time of onset of infection
- Necrotizing fasciitis (NF) and Streptococcal Toxic Shock Syndrome (STSS) are forms of invasive GAS infection and should be reported in the above situations.

# **i**GAS Case Definition Details

- Normally sterile body sites: such as blood, cerebrospinal fluid (CSF), pleural fluid, peritoneal fluid, pericardial fluid, surgical aspirate, bone, joint fluid, or internal body site (e.g., lymph node, brain)
- Residential Facility: (e.g. long-term care facility including skilled nursing facility, assisted living, ICF/DD, SMHRF, SLF, etc.; correctional facility including prison, jail, or juvenile justice facility; university or residential school; homeless shelter; group home; or other residential facility)

# **i**GAS Case Definition Details cont.

- Is postpartum
  - Associated with a clinical postpartum infection (e.g., endometritis) or from either a sterile site or a wound infection.
  - Postpartum period of interest includes all inpatient days and the first 7 days after discharge.
- Is postsurgical
  - Identified during the hospital stay or the first 7 days after discharge
  - From a sterile site or a surgical wound
  - The indication for surgery was not a preexisting GAS infection
- Hospital onset
  - Hospitalized at the time of onset of infection
  - Infection was neither present on admission nor incubating at the time of admission.
  - Sample taken on hospital day 4 or later and symptoms associated with iGAS were not present on admission.
  - Reason for admission was unrelated to GAS infection, either invasive or non-invasive.



- Please indicate in the comments if:
  - The patient resides in a residential facility if not obvious from the address.
  - The patient is postpartum include date of delivery.
  - The patient is postsurgical include date of procedure and indication.
  - The case is hospital onset make sure the admission date and specimen collection date are correct.
  - If these situations do not apply, please indicate "not postpartum," "no surgery," etc.
- CDPH may still need some additional information depending on the scenario.

_Jurisdiction				
Select a Jurisdiction:	Illinois Dept of Public Health Central Office 🗸			
_Other Information_				
Comment: (Include any additional pertinent information.)				
Additional Required Information         Clinical - Add or update patients clinical information.         Laboratory Tests - Add or update laboratory test information.				

\*\*Please fax the laboratory confirmation report to your local health department (LHD).\*\*

( * ) Mandatory					
Submit to LHD	Save As Draft	Change Diagnosis	Copy Case	Cancel	

# **XDRO Point Prevalence Surveys**

- CDPH may be able to come to your facility for a prevention or a response PPS.
- We test for CRE (peri-rectal swab) and C. auris (axilla/groin swab)
- If your facility is interested:
  - CDPH PPS Lead will reach out and walk you through the process
  - All levels of support will be provided by CDPH, including expense
  - What CDPH needs from you:
    - A current list of all residents with demographics, room/bed, indwelling devises, CP status
    - Rolling carts
    - Some staff support on the floor to help identify and locate residents
    - Reach out to Maria Bovee if interested in participating

# **CDPH** Supported Point Prevalence Survey

CDPH also conducts periodic preventative PPSs at SNFs based on the Patient Transfer Network analysis.

If your facility is selected:

- CDPH PPS Lead will reach out and walk you through the process.
- All levels of support will be provided by CDPH, including expenses.
- What CDPH needs from you:
  - A current list of all residents with demographics, room/bed, indwelling devises, CP status.
  - Rolling carts
  - Some staff support on the floor to help identify and locate residents.



# Respiratory Disease Surveillance Review and Updates for the Coming Season

IP Round Table - 9/19/2024

**Stephanie Gretsch** 

# Influenza activity in Chicago during the 2023-24 season was similar to previous non-pandemic seasons.

- 2023-24 season was moderately severe across all ages
- The most commonly detected influenza viruses for the season as a whole were influenza A(H1N1)pdm09 viruses.
- The cumulative hospitalization rate is the second highest cumulative end-ofseason hospitalization rate following the 2017-2018 season.
  - Older adults 65+ and 50-64 y/o followed by children <5 most affected</li>



# Influenza lab percent positivity peaked lower (14.5%) and later (in December) than last season.



Traditional Influenza Season October - May

# There was a second peak (9.4%) in March mainly associated with influenza B.



Traditional Influenza Season October - May 15

### Similar trends seen among emergency department visits due to Influenza (DDx)



Week Ending Date

#### Weekly Reported Influenza-Associated ICU Hospitalizations 2017-2018 to 2023-2024



Week Ending Date

# Cumulative ICU rates highest since the COVID pandemic but below prior influenza seasons



# 15 influenza outbreaks in long-term care facilities were reported, almost double than last season.



### No reported pediatric influenza deaths in Chicago last season, but 199 reported in the US, equaling the previous high during the 2019-2020 season



# During the 2023-2024, COVID test positivity peaked in December (11.9%), similar to last season. However, a summer peak (15.0%) occurred in August.



21

# However, ED Visits Due to COVID-19 (DDx) were higher in December than during this current summer wave



# RSV seasonality was disrupted following the COVID Pandemic but has started to shift back to normal seasonal patterns



November - March

23

### Emergency Department Visits Due to RSV (DDx) in Children <5 years



Week Ending Date

### Upcoming 2024–25 season peak hospitalization burden likely similar to or lower than last year



Combined peak hospitalization burden of COVID-19, influenza, and RSV

#### Could be worse if:

- New COVID variant
- Predominance of influenza subtype with more severe outcomes
- Lower vaccine uptake or effectiveness

#### Possible scenarios for weekly COVID-19 hospitalizations for 2024-2025 respiratory season



# Data suggests that this flu season was similar to revious flu seasons in the Southern Hemisphere.

#### South America:

- Flu activity has been primarily attributed to influenza A(H3N2) viruses, though influenza A(H1N1) and B viruses have also been reported.
- Some countries experienced very high levels of flu activity, but most reported moderate or low flu activity levels similar to levels observed in prior seasons.

#### Africa:

- Influenza A(H1N1) viruses have predominated in Africa, though influenza B detections have increased in recent weeks.
- So far, most African countries have remained at low and moderate levels of influenza detections during the 2024 season.
- Australia:
  - Influenza A(H3N2) viruses were predominant among subtyped viruses.
  - Australia's 2024 flu season had a similar start week compared to both pre-pandemic trends and the previous 2023 season.
  - Influenza detections briefly reached moderate levels but have been decreasing in recent weeks, though several jurisdictions continue to show increasing flu activity

# What's going on right now







(C) displays the quartile of each week's geometric mean concentration for each site. Quartiles are calculated using all data from each respiratory season.



03/24/24 03/31/24 04/07/24 04/14/24 04/21/24

MMWR Week

/28/24 /05/24 26/24 /02/24 /09/24 /16/24 /23/24 /30/24 /30/24 /12/24 /21/24 /21/24 8/04/24 8/11/24 M8/24 /25/24 /01/24 /08/24 /15/24

1/26/23

12/03/23

12/17/23 12/24/23 12/31/23

2/10/23

01/14/24 01/21/24 01/28/24 02/04/24

/07/24

02/18/24 02/25/24 03/03/24 03/10/24 03/17/24

02M1/24

1 / 1 2 / 2 3 1 / 1 9 / 2 3

1/05/23

PS.Rac WPull/Rose

19M 7/23

09/24/23 10/01/23 10/08/23

09/03/23 09/1 0/23 0// 5/23 0/22/23 0/29/23

# **Respiratory Virus Percent Positivity Seasonal Trends**



Week Ending Date

### Emergency Department Visits Due to Influenza-like Illness (ILI)



Week Ending Date

# **Outpatient Visits Due to ILI (ILINet)**



Week Ending Date

# Avian Influenza A (H5N1) Situation

 No indicators of unusual flu activity in people, including avian influenza A(H5N1) viruses. Overall risk assessment still low.

Total Reported Human Cases of H5 in the United States since 2022	15
Human Cases of H5 Following Exposure to Dairy Cows since April 1, 2024	4
Human Cases of H5 Following Exposure to Poultry since April 28, 2022	<b>10</b> (9 in 2024)
Human Cases of H5 with No Immediately Known Animal Exposure	<b>1</b> (Missouri case reported 9/6/24)*
States with Reported Case(s)	Colorado, Michigan, Missouri, Texas

- As of September 13, 2024, USDA is reporting that 202 dairy cow herds in 14 U.S. states have confirmed cases of avian influenza A(H5N1) virus infections in dairy cows as the number of infected herds continues to grow.
- Most recently, outbreaks in cows on eight California dairy farms were confirmed.
- USDA reports that since April 2024, there have been A(H5) detections in 35 commercial flocks and 22 backyard flocks, for a total of 18.68 million birds affected.
- No H5 detections have been identified on Illinois farms.

# **CDPH H5 Surveillance Activities**

- Wastewater Surveillance
  - Monitoring for high levels of influenza A and conducting H5 dPCR testing if high levels detected.
  - Currently, CDPH has not had any H5 detections in tested samples.
- Symptom monitoring for exposed individuals
  - CDPH has a protocol to monitor individuals that have worked on farms where H5 has been detected and return to Chicago after contract work has ended.
  - Less than a dozen individuals have been monitored this year.
- Laboratory-based surveillance
- Monitoring usual human influenza surveillance systems for unusual activity over the summer
# **\*** When to submit influenza specimens for typing

- In general, these are the two main categories where we would recommend a specimen be sent to IDPH for subtyping:
  - 1. If a rapid test is performed on an ICU patient and it is positive for influenza A: the recommendation is to send that specimen to IDPH lab for further subtyping, the hospital doesn't need to subtype if they don't want to. This doesn't apply to ED or outpatient visits. \*unless of course there is a high suspicion for HPAI in which case they should consult with CDPH and we can advise.
  - 2. If a lab performs an influenza test on a platform that does subtype and the result is influenza A, but it was not subtypeable (meaning they tried but couldn't), IDPH recommendation is to send that specimen to IDPH lab to subtype. Regardless of level of care.
- And this only applies to positive influenza A specimens (not influenza B).
- CDPH is not recommending any specific types of tests to be used.

## $\star$ New reportable conditions this season

	COVID-19	Influenza	RSV
ICU Admissions (lab-confirmed)	NEW	Existing	NEW
Pediatric deaths	NEW	Existing	NEW
Positive laboratory tests*	Existing	NEW	NEW

\*Electronic laboratory reporting (ELR) only

Report within 24 hours

# **X** Common reporting issues so far

- Lags in reporting or no reporting so far
- Missing ICU information



- Influenza with ICU Hospitalization
- Respiratory Syncytial Virus (RSV) with ICU Hospitalization
- SARS-CoV-2 infection (COVID-19) with ICU Hospitalization
- Pediatric Influenza Death
- Pediatric Respiratory Syncytial Virus (RSV) Death
- Pediatric SARS-CoV-2 infection (COVID-19) Death

Disease	
Staphylococcus aureus Vancomycin	-

(\*) Mandatory (A)

Cancel

ΟK



## **Case Details**

User Name: Test User One Provider

\_Patient Information\_

First:*			
Middle:			
Last:*			
Suffix: 🗸			
DOB: (mm/dd/ccyy)*		Current Age:	Years V
Sex at Birth:	✓	Current Gender:	~
Ethnicity:	~		
Deceased:	~	Deceased Date: (mm/dd/ccyy)	
	Available		Selected
Races:	American Indian or Alaskan Native Asian Black or African American Native Hawaiian/Other Pacific Isla	Add >>	
Address Line 1:	(Enter street address only. Example: 1	234 W Main Street)	
Address Line 2:	(Enter PO Box#, Suite#, Apt#, Room#	;, etc.)	
City:			
State:	Illinois 🗸	Zip Code:	-
County:	<b>~</b>	Country: United	States 🗸
Community Area:	✓ (Applica	able for Chicago only.)	
Home Phone #:	()	Cell Phone #: (	)

## Patient Demographics

Disease:	Respiratory Syncytial Virus (RSV) with ICU Hospitalization
Earliest Report	
Date: (mm/dd/ccyy)	
Disease/Onset Date: (mm/dd/ccyy)	
Was the patient seen in an	
emergency	✓
department due to the disease?	
ER Hospital:	
If ER hospital not found,	
enter information here:	
Was the patient	
admitted to a hospital due to the disease?	
Was the hospital admitted to	
same as ER?	
	on for the hospital admitted to if it is different from the ER Hospital.
Hospital admitted to:	
If hospital not found,	
enter	
information here:	
Admission Date: (mm/dd/ccyy)	
Discharge Date: (mm/dd/ccyy)	
Is the Patient Pregnant?	~
Estimated Due Date: (mm/dd/ccyy)	

## **Disease onset**

## ED and Hospitalization

## \_Physician Information\_

Physician:

If not found in Physician Dropdown:

If physician not found in dropdown or through search, enter information here:

### \_Reporter Information\_

Name: Test User One Provider

Phone: (217) 333-4444

### \_Reporting Organization Information\_\_\_\_\_

Type:	Hospital
Name:	Sherman Hospital
Address:	1425 North Randall Road Elgin, IL 60123-2300

#### Other Reporting Organization:

#### Jurisdiction.

Select a Jurisdiction:

Illinois Dept of Public Health Central Office 🗸

Search Physician

~

## Other Information\_\_\_\_\_

Comment: (Include any additional pertinent information.)

## **Provider info**

## Your info

## Comments

!Please include if patient lives or works in a congregate living setting (e.g., nursing home, corrections, group home)!

# **X** Disease specific additional info

## Additional Required Information

<u>Clinical</u> - Add or update patients clinical information. <u>Treatment and Immunization</u> - Add or update patients treatment information. <u>Laboratory Tests</u> - Add or update laboratory test information. <u>Epidemiologic Data</u> - Add or update all epidemiologic data.

## **Clinical Info Section**

Fever ( <u>&gt;</u> 100.4 F or <u>&gt;</u> 38 C):	~
Highest recorded temperature if available	
Cough:	✓
Sore Throat:	<b>~</b>
Fever/chills (subjective)	<b>~</b>
Wheezing:	<b>~</b>
Shortness of breath/resp distress	<b>~</b>
Apnea	<b>~</b>
Congestion/runny nose	<b>~</b>
Diarrhea:	<b>~</b>
Nausea/Vomiting:	<b>~</b>
Dehydration:	<b>~</b>
Ear ache/ear infection	<b>~</b>
Myalgia/muscle aches	<b>~</b>
Seizures	<b>~</b>
Cyanosis:	<b>~</b>
Tachypnea	<b>~</b>
Hypothermia	<b>~</b>
Inability to eat, poor feeding	~
Decreased vocalization or stridor	~
Lethargy, less active or sleepy	~
Other	✓

Symptom history

Complete as much as is known

## **Clinical Info Section**



#### Does the patient have any of the following secondary infections or complications?

Altered mental status	~
Bronchiolitis	✓
Encephalitis:	~
Myocarditis (Infection of heart muscle):	~
Pneumonoa (Chest X-ray confirmed)	✓
Pulmonary hypertension	✓
Seizures	<b>~</b>
Acute Respiratory Distress Syndrome (ARDS):	~
Secondary bacterial infection	✓
Sepsis/multi-organ failure	~
Other Complications	~
Specify Other Secondary Complications:	

## Complications

## **Clinical Info Section**

×

Does the patient have any of the following pre-existing underlying conditions?

Asthma/reactive airway disease	~
Neuromuscular disorder	✓
Neurological disorder(e.g., cerebral palsy, seizure disorder, developmental delay, etc.)	✓
Liver Disease:	✓
Prematurity	✓
If yes, specify gestational age at birth in weeks	
Active Cardiac Disease (e.g., congestive heart failure):	✓
If yes, what type of active cardiac disease does the patient have?	
Other Lung Disease (e.g., COPD, emphysema, lung cancer):	✓
If yes, what type of chronic lung disease does the patient have?	
Diabetes:	✓
End Stage Renal Disease (or dialysis):	✓
Hemoglobinopathy (e.g., sickle cell disease):	
Immunosuppression:	✓
If yes, describe (e.g., AIDS, steroid use):	
Other underlying condition:	✓
Specify Other Conditions:	
Is the patient a child (<18 years) on chronic aspirin therapy?	✓
	Save Cancel

Pre-existing underlying medical conditions

## **Treatment and Immunizations**



## This is where you report ICU admission info!

Was the patient hospitalized in the Intensive Care Unit?

If yes, Date Admitted to ICU: (mm/dd/ccyy)

If yes, Date Discharged from ICU: (mm/dd/ccyy)

Was the patient on a ventilator?

#### **Immunization Information**

Did the patient receive RSV vaccine for the current season?

If yes, Date of Vaccination: (mm/dd/ccyy)

Type of Vaccine:

#### Antiviral Medications

Did the patient receive antiviral medications?

If yes, Date Initiated: (mm/dd/ccyy)

If yes, Date Discontinued: (mm/dd/ccyy)

Drug:

Specify other treatments







Save Cancel

## **Laboratory Tests**



(RDS)?

Were human laboratory tests conducted?	Yes	~
Confirmed Case: ICU Hospitalization AND positive PCR, Culture, IFA or EIA Probable Case: ICU Hospitalization AND positive rapid test		
Which RSV subtype did the patient test positive for?		
Was a chest X-ray or chest CAT scan performed?		~
If yes, did patient have radiographic evidence of pneumonia or respiratory distress syndrome		

Collection	Specimen	Laboratory	Ordering Facility	Facility Phone
Specimen Number				
	Test Type		Test Result	

Save Add Lab Specimen	Cancel
-----------------------	--------

## Must have labconfirmation to be reported

~

## **Epidemiologic Data**

Has the patient smoked in the last year?

- If yes, for how many years?
- Was the patient a former smoker?
  - If yes, for how many years?
- Has the patient used combustible THC in the last year?
  - If yes, for how many years?
- Has the patient used e-cigarette or vaping products in the last 90 days?
  - If yes, has the patient used nicotine based e-cigarette or vaping products?
  - If yes, has the patient used cannabis based e-cigarette or vaping products?

Save

Cancel

- If yes, has the patient used CBD based e-cigarette or vaping products?
- Reporting source for smoking and vaping questions?

Other:



×

## Report if available but not priority



- Planned launch for communicable disease conditions, including COVID-19, Influenza and RSV at the end of October – exact date has not been announced
- IDPH CD section chief speaking at next roundtable
- Training for LHD staff not conducted yet we all have a lot to learn ③

# **\*** Reporting of Hospital Respiratory Data to NHSN

- Reporting starts November 1, 2024. Modules will soon be live on NHSN application.
  - This is a CMS reporting requirement for all acute care hospitals, long-term acute care hospitals, freestanding rehabilitation facilities, freestanding psychiatric facilities, Children's hospitals and other facility types.
- Hospital respiratory data reporting **will replace** Hospital Respiratory Pathogen, Bed Capacity, and Supply Data.
- Encompass many of the same data elements: capacity and occupancy, hospitalized patients and new admissions with lab confirmed COVID-19, Influenza, and RSV; hospital PPE and supply information.
- All reporting modalities will continue to be available.
- Cadence: option to report once per week (on Tuesdays by 11:59 PM) OR daily
- **Bookmark** <u>Hospital Respiratory Data | NHSN | CDC</u> for important updates, additional resources, and webinar training information.



## **Data Elements**

 Total of 58 data elements will be available for reporting, of which 48 are required, while 10 are optional:

REQUIRED	48	OPTIONAL	10
New admissions (COVID-19, influenza, RSV)	21	Days on hand supplies	5
Prevalent hospitalizations (COVID-19, influenza, RSV)	12	Able to maintain supplies	5
Pathogen agnostic bed capacity and occupancy	12		
Facility information and datetime fields	3		

## **REQUIRED Data Elements – Weekly Snapshots**

 Of the 24 required weekly snapshots, 12 data elements collect information on pathogen-specific prevalent hospitalizations and ICU hospitalizations

Prevalent hospitalizations	6 elements total	ICU hospitalizations	6 elements total
CO)//D 10	All hospitalized adult patients with laboratory-confirmed COVID-19	CONTD 10	Adult ICU patients with laboratory- confirmed COVID-19
COVID-19	All hospitalized pediatric patients with laboratory-confirmed COVID-19	COVID-19	Pediatric ICU patients with laboratory- confirmed COVID-19
_	All hospitalized adult patients with laboratory-confirmed influenza	-1	Adult ICU patients with laboratory- confirmed influenza
Flu	All hospitalized pediatric patients with laboratory-confirmed influenza	Flu	Pediatric ICU patients with laboratory- confirmed influenza
Paul	All hospitalized adult patients with laboratory-confirmed RSV	DCV	Adult ICU patients with laboratory- confirmed RSV
RSV	All hospitalized pediatric patients with laboratory-confirmed RSV	RSV	Pediatric ICU patients with laboratory confirmed RSV



# Infection Prevention and Control Recommendations: Respiratory Virus

IP Round Table – 9/19/2024 Karen Branch-Crawford, RN, BSN, CIC Infection Prevention Specialist

# Respiratory Viruses: Summary of Recommendations

- Use masks and respirators to help decrease the spread of respiratory viruses.
- Get vaccinated and <u>encourage patients to do the same</u>.
- Practice physical distancing and implement screening and triage procedures.
- Practice respiratory hygiene and cough etiquette.
- Keep your hands clean.
- Clean and disinfect. Make sure you read labels correctly when using disinfectants.
- Check that the air handling in your facility is functioning as it should.
- Infection Control Guidance: Respiratory Viruses | Project Firstline | CDC

Summary of Infection Prevention Recommendations for Respiratory Virus-adapted from Appendix A (Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings (2007)

		Facilities might have different requirements/protocols.				
		COVID-19	RSV	Seasonal Influenza		
	PPE	N95 mask. Surgical mask if N95 unavailable. Gown, Gloves Eye protection* *Use eye/face protection if <b>aerosol-</b> <b>generating procedure</b> performed or contact with respiratory secretions is anticipated.	Surgical mask Gown Gloves Eye protection* *Use eye/face protection if aerosol-generating procedure performed or contact with respiratory secretions is anticipated.	Surgical mask Gown Gloves Eye protection* *Use eye/face protection if aerosol-generating procedure performed or contact with respiratory secretions is anticipated.		
	Isolation Type	Airborne + Droplet + Contact + Standard	Droplet + Contact + Standard	Droplet + Standard		
С	Special Ventilation	Use Caution when Performing Aerosol-Generating Procedures: <b>use airborne infection isolation room (AIIR) when feasible</b> . Considering use of portable HEPA filtration units to further reduce the concentration of contaminants in the air.				
	Cleaning and Disinfection	Use products according to label instructions and use products that are on <u>EPA's List N: Disinfectants for</u> <u>Coronavirus</u> . Review directions for use, kill claims, contact time.	Use products according to label instructions. Review with staff directions for use, kill claims, contact time.			

## **Infection Prevention Recommendations for Respiratory Virus**

×		COVID-19	RSV	Seasonal Influenza	
	Vaccine	1 or more doses of the current COVID –19 vaccine depending on age or health status. Anyone ages 6 months and older For more information: <u>www.cdc.gov/covidschedule</u>	1 dose • adults age 75+ • Adults ages 60 -74 increased risk • Pregnant people 32 -26 weeks • Babies given after birth • Children 8 – 19 months	1 dose each year Anyone ages 6 months and older	
	Hospital Exposures	<ul> <li>Testing (3 viral tests) and work restriction of symptomatic HCP (higher-risk exposures).</li> <li>Testing recommendations: <ul> <li>Day 1, 3 and 5.</li> </ul> </li> <li>Follow your facility's work restrictions Work restriction is not necessary for most asymptomatic HCP following a higher-risk exposure, regardless of vaccination status.</li> </ul>	Symptomatic HCP should be excluded from work until fever free for 24 hours		
	Reporting Requirements	<ul> <li>ICU admission</li> <li>Pediatric Death &lt;18 years of age</li> <li>Outbreaks</li> </ul>	atric Death <18 years of age		
	Patient Placement	When a single patient room is not available, consultation			



#### **CDC Guidelines:**

- Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings (2007) (cdc.gov), Last update: July 2023
- Appendix A: Type and Duration of Precautions Recommended for Selected Infections and Conditions | Infection Control | CDC
- Appendix A: Table 2. Clinical Syndromes or Conditions Warranting Empiric Transmission-Based Precautions in Addition to Standard Precautions | Infection Control | CDC

#### Covid-19

- <u>https://www.cdc.gov/covid/hcp/infection-control/?CDC\_AAref\_Val=https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-</u> recommendations.html#cdc\_infection\_control\_background-1-recommended-routine-infection-prevention-and-control-ipc-practices-during-the-covid-19-pandemic
- <u>https://www.cdc.gov/covid/hcp/infection-control/guidance-risk-assesment-hcp.html</u>
- https://www.cdc.gov/coronavirus/2019-ncov/community/ventilation.html
- <u>https://www.cdc.gov/project-firstline/media/images/Ventilation-508.jpg</u>
- https://www.cdc.gov/healthcare-associated-infections/media/pdfs/environmental-cleaning-rls-508.pdf

#### Influenza

- <u>https://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm#anchor\_162091279860</u>
- <u>https://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm</u>
- <u>https://dph.illinois.gov/topics-services/diseases-and-conditions/respiratory-disease/diseases/influenza.html</u>

#### RSV

<u>https://www.cdc.gov/rsv/hcp/clinical-overview/index.html</u>

# **X** Project First Line: Respiratory Packet (NEW)

## PFL Respiratory Packet

 Prepare Your Clinics and Patients for Fall and Winter Respiratory Virus Season With CDC Director and AMA











- How are facilities prepared to report Hospital Respiratory Data in light of the new CMS/NHSN respiratory burden requirement?
- Have any other facilities, particularly those using Epic, successfully built a report to utilize the CSV template/upload feature for this requirement?
- If so, how do these facilities handle the reporting process compared to manually collecting the data in the PDF form?



# Thank you for participating!Next Meeting (on Teams): Thursday, October 17, 2:00 PM<br/>Main Presenter: Judy Kauerauf, MPH<br/>Communicable Disease Section Chief, Division of Infectious Diseases, IDPH









# Additional Slides/Resources

(not presented during the meeting)



Our team consists of Infection Prevention Specialists, Epidemiologists, Project Managers, Projects Administrators, and Medical Directors who provide the following assistance:

- IP&C Guidance and Training
- Infection Control Assessments and Responses (ICARs)
- Epidemiology Support
- IP&C Roundtable
- Our partnerships and site visits are meant to be educational, constructive, non-regulatory, and non-punitive
  - We work with you to resolve any identified issues
  - These services are not in response to citations or complaints



- CDPH requires additional epidemiological information for specific cases, in addition to the standard reporting requirement. Providing this information to CDPH allows us to have a better understanding of individual case and aids in limiting the transmission of certain multi-drug resistant organisms.
- For MDRO Reporting training (whether you have a new IP or need a refresher) and for questions regarding CRF completion requirements, please contact Cecilia Pigozzi at <u>cecilia.pigozzi@cityofchicago.org</u>





# 🖈 Project Firstline Overview

- Project Firstline is the Center for Disease Control's (CDC) National Training Collaborative for Healthcare Infection Control education
- Project Firstline (PFL) brings together more than 75 healthcare, academic, and public health partners to reach healthcare workers across the country
- PFL offers educational resources in a variety of formats to meet the diverse learning needs and preferences of the healthcare workforce

## As of May 2022, Project Firstline and its collaborative partners have:



Developed **200+** educational products and training materials on healthcare infection control



Hosted **750+** educational events, reaching approximately **65,238** healthcare workers

Received **84 million+** views across the web and various digital platforms



- Learn about Infection Control in Health Care: CDC's Project Firstline provides innovative and accessible resources so all healthcare workers can learn about infection control in health care.
  - Topics include 14+ foundational IP&C (e.g., hand hygiene, environmental services, ventilation, PPE, how viruses spread, etc.), <u>Recognizing Risk using Reservoirs</u>, <u>Where</u> <u>Germs Live training toolkits</u>, and more interactive resources.
- Lead an Infection Control Training: Our facilitator toolkit is designed to work with your team's learning styles and busy schedules (10-, 20-, and 60-minute scripted sessions).
- <u>Access Infection Control Educational Materials</u>: Find short videos, fact sheets, job aids, infographics, posters, <u>printed materials</u>, interactive computer lock screens, and social media graphics to utilize at your facility on foundational IPC topics.
- Earn Continuing Education: Earn CEU's on CDC Train for PFL content.
- Translated Resources: IPC materials translated into Spanish & additional languages.

# **Infection Control Training Topics** (Onsite/Virtual with IDPH CEU/CEC)

- 1. The Concept of Infection Control
- 2. The Basic Science of Viruses
- 3. How Respiratory Droplets Spread COVID-19
- 4. How Viruses Spread from Surfaces to People
- 5. How COVID-19 Spreads A Review
- 6. Multi-Dose Vials
- 7. PPE Part 1 Eye Protection
- 8. PPE Part 2 Gloves & Gowns

- 9. Hand Hygiene
- 10. Virus Strains
- 11. PPE Part 3 Respirators
- 12. EVS (Enviro Cleaning & Disinfection)
- 13. Source Control
- 14. Asymptomatic Spread of COVID-19
- 15. Ventilation

# **X** Print Materials & Job Aids

- Several print materials and job aids available on foundational IP&C topics.
  - Available for free download on CDC's website.
  - Including lock screens for staff computers.
- We are happy to offer professional printing support for poster requests!
  - Please see our team after the presentation to request print materials.
  - For remote guests, please email: projectfirstline@cityofchicago.org.



work?

Needlestick accidents

are the most common way that bloodborne

viruses are spread in healthcare

🗶 🗠 🗠 🐨 👘 🖬 Alistore

Recognize the risks. Take action to stop the spread of germs. Learn more at CDC.GOV/PROJECTFIRSTLINE



[PDF - 1 Page]

Germs are everywhere, including on surfaces and devices in the healthcare environment.

Learn how to stop their spread: WWW.CDC.GOV/PROJECTFIRSTLINE





# INFECTION CONTROL PROTECTS







The right infection control actions help stop germs from spreading.

Learn more: WWW.CDC.GOV/PROJECTFIRSTLINE







# 2023 LEARNING NEEDS ASSESSMENT

## WE WANT YOUR FEEDBACK TO DEVELOP NEW CONTENT!

- CDPH is a proud partner of CDC's National IP&C Training Collaborative, Project Firstline.
- We are working to identify priority
   IPC training needs among your
   frontline healthcare staff.
- This brief survey (<10 minutes) helps us develop relevant content for your and your team.
- These trainings will be developed for our Fall 2023 IPC webinar series (with free CEUs)!

# **X** Your Chicago Project Firstline Team

- **CDPH Infection Preventionist**: Your facility's main contact for all infection prevention and control questions.
  - General contact information: cdphhaiar@cityofchicago.org
- **PFL-CDPH Team**: Contact our team to learn about specific Chicago-based educational opportunities!
  - We offer many resources including virtual or onsite trainings, webinars, and job aides.
  - CDPH Project Firstline email: projectfirstline@cityofchicago.org





Visit our <u>Chicago Health Alert Network (HAN)</u> page by scanning the QR code in the shield logo above to access resources and sign up for the newsletter to stay up to date on exciting new IPC resources!



Are non-regulatory and non-punitive

Facilitate collaboration among facility departments

Provide learning opportunities in critical areas

Help facilities prepare for Joint Commission surveys

Increase involvement of facility leaders in infection prevention work

## Infection Control Assessment Tools | HAI | CDC

Click on each module below to open the tool in a fillable PDF document.

Module 1 – Training, Audits, Feedback Module 2 – Hand Hygiene Module 3 – Transmission-Based Precautions (TBP) Module 4 – Environmental Services (EVS) Module 5 – High-level Disinfection and Sterilization Module 6 – Injection Safety Module 7 – Point of Care (POC) Blood Testing Module 8 – Wound Care Module 9 – Healthcare Laundry Module 10 – Antibiotic Stewardship Module 11 – Water Exposure